Acquisitions:

1. Anupam Rasayan completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma for about Rs 1,750 crore (US$183.2 Million), through its subsidiary Mates Visa Consultancy, marking its entry into finished dosage formulations.
2. Novartis India to acquire Pfizer hypertension brand Minipress for ?1,250 crore (US$131.25 Million).
3. Novartis to acquire Sironax's brain delivery platform.
4. Sanofi Healthcare buys 15.2% stake in India subsidiary for Rs 1,068 crore (US$111.39 Million).
5. Lisata Therapeutics acquired Marea Therapeutics, adding several late-stage cardio-endocrine candidates, alongside a concurrent US$225 Million private placement.
6. Grünenthal agreed to acquire Bayer's oncology drug Stivarga (regorafenib), approved in more than 90 markets, for up to €375 Million (US$431 Million); closing is expected by end-2026 or early 2027.

Licensing:

1. Cipla has entered into an exclusive licensing agreement with Sino Biopharmaceuticals (SBP Group) to develop and commercialize Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC (bsADC), in India, South Africa and 5 other Emerging Markets, thereby strengthening Cipla's innovative oncology portfolio.
2. Sun Pharma signed an exclusive licensing agreement with US-based LIB Therapeutics to manufacture and commercialise lerodalcibep (Lyrokaul), a once-monthly PCSK9 inhibitor for LDL-C lowering, worldwide excluding the US and China.
3. Cipla licenses China's Qilu Pharmaceutical Keytruda biosimilar US rights.
4. Shilpa Biologicals, SPIMACO sign MENA licensing deal for PD-1 biosimilars.
5. Novartis India enters exclusive distribution deal with NHPL for retina portfolio.
6. RPG Active Pharma acquires Raghava Life Sciences' API business for up to Rs 135 crore (US$14.1 Million).
7. Dr. Reddy's expands collaboration with Gilead Sciences for investigational once-yearly lenacapavir for HIV prevention.
8. Orbis Medicines signs up to US$1.4 Billion deal with Novo Nordisk.

Investments/Fund Raising:

1. Ultrahuman (Bengaluru, health wearables) raised US$70 Million from Qualcomm Ventures, Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital.
2. Prodoc AI (Bengaluru, hospital AI) raised an undisclosed seed round led by the family office of Thyrocare founder Dr A. Velumani.
3. Nua (Mumbai, women's health) raised Rs 477.5 crore (US$50 Million) in a Series C led by Peak XV Partners and Filter Capital; part of the round was secondary.
4. Encoded Therapeutics raised a US$275 Million Series F to fund a pivotal study of ETX101 in SCN1A+ Dravet syndrome.
5. Solstice Oncology launched with a US$225 Million Series A led by RA Capital Management to develop porustobart, an Fc-enhanced CTLA-4 antibody, in microsatellite-stable colon cancer.

1. New Client Win: Aagami has been appointed by a venture-backed biopharma company for out-licensing for its First-in-Class, Phase 3-complete topical Antimicrobial Peptide (AMP) spray across target Asian markets, starting with India. The asset features a novel, non-drug-resistant mechanism targeting mixed skin/skin structure infections (including burn wounds and diabetic foot infections), supported by strong clinical efficacy data published in JAMA Network Open and Burns & Trauma, a 2041 formulation patent barrier, and an exclusive Master API supply model.
2. Aagami CEO Dinesh Jain, is attending BioJapan 2026 (October 7–9 | Yokohama) with more than 25 one-to-one partnering meetings scheduled.
3. Aagami VP Godwyn Francis, is attending Bio Europe 2026 ( November 9–11 | Cologne Germany). Partnering now open, please send your meeting request on the platform at the earliest.

Market Stage Assets For Licensing/Partnering

1. Licensing Available: FDA-Cleared Portable MRI & AI Guided Robotics Surgery Platform for Prostate Cancer. Applicable for other indications too. 290+ systems sold and $195M in cumulative orders to date across 32+ U.S. states & 19 countries.
2. Seeking Partner / Distribution: CE-marked single-injection bioresorbable implant (KioMedine ^VSOne) for Knee Osteoarthritis (OA). Patented non-animal carboxymethyl-chitosan with unique ROS-scavenging action. One Injection. Delivers 9–12 months of pain relief; proven efficacy in HA/steroid-refractory patients. Marketed across 25 countries.
3. First-in-class, broad-spectrum antimicrobial peptide (Peceleganan / PL-5) targeting bacterial & fungal cell membranes with low resistance potential. Market-approved in China for burn wound infections (Phase 3b complete) and Phase 2-ongoing in the US for Diabetic Foot Infections (DFI).
4. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit making product. Licensing available. US$ 40.2M Sales in 2025 in USA.
5. High ROI Opportunity to Partner in another U.S. (California) based medtech revolutionizing medical imaging, diagnosis and robotic surgery for Brain and Head (US FDA cleared). Focus on Strokes and TBI. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.

[In-Development Stage]

1. Phase 3 stage small molecule eye drop to treat Cataract (First in class). Brings paradigm shift in OPTH. Uses known molecule.
2. Phase 3 stage Erythropoietin (EPO) asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). Seeking strategic partner/investment, and EPO supplier also.
3. Phase 2 Broad-Spectrum Revolutionary Antiviral (PRV Eligible). Includes the Coronavirus family, including SARS-CoV-2 (COVID, Long COVID), RSV, Influenza A (including H5N1 "Bird Flu"), as well as Smallpox/MPOX, Measles and Ebola.
4. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028-29 market launch timeline.
5. Phase 3-Ready Biological Franchise for Smoking Cessation. 2 Injection dosing regimen with no side effect. Phase 2 completed.
6. Seeking Licensing/Partnering: Biobetters Clinical-stage portfolio of 2nd & 3rd-gen therapeutic enzymes (Phase 1) engineered to address known immunogenicity and short half-life limitations. Targets include PKU, ALL/LBL, and ASS1-deficient solid tumors, featuring extended dosing intervals and strong safety profiles. Estimated market approval ~2029-2030
7. Seeking Licensing/Partnering: Phase 3-Ready Drug safety-optimized to treat Atrial Fibrillation (AF);eliminates 3-day hospital onboarding for outpatient prescribing (dofetilide + mexiletine). FDA protocol reviewed, addressing 33M+ patients global market with >$1B peak sales potential.

For Investment:

1. High ROI Opportunity to Invest in U.S. based MedTech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform for Prostate Cancer (On the market). Currently raising last round - Series C targeting up to $70M. Exit via an IPO, strategic M&A, or private equity buyout.
2. Seeking Investment ($30–$40 Million Series A): High-ROI opportunity in Phase 3-ready cardiovascular drug targeting Atrial Fibrillation with >$1B peak annual sales potential. Funds will be used for Phase 3 clinical trials, CMC manufacturing readiness, and FDA NDA filing. Exit via Strategic M&A or IPO.
3. Seeking Investment (US$ ~3.76 Million raised in 2026): Join Investors such as BIRAC in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
4. High ROI Opportunity to Invest in another U.S. (California) based medtech revolutionizing medical imaging for Brain and Head (US FDA cleared). Exit via an IPO, strategic M&A, or private equity buyout. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.

For Acquisition:

1. [URGENT] Lucrative (Less than $300K) Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing. 2 Bids under evaluation by Bankruptcy Trustee.
2. Available at a very reasonable price - Mountain View Pharma (MVP) including its PharmaPEG® technologyfor Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc.
3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

Hope you found the content useful. 

We welcome your feedback and queries.